<VariationArchive RecordType="classified" VariationID="1013603" VariationName="NM_000138.5(FBN1):c.4878del (p.Phe1626fs)" VariationType="Deletion" Accession="VCV001013603" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-12-11" DateCreated="2021-03-14" MostRecentSubmission="2021-03-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1001321" VariationID="1013603">
      <GeneList>
        <Gene Symbol="FBN1" FullName="fibrillin 1" GeneID="2200" HGNC_ID="HGNC:3603" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="48408313" stop="48645709" display_start="48408313" display_stop="48645709" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="48700502" stop="48937984" display_start="48700502" display_stop="48937984" Strand="-" />
          </Location>
          <OMIM>134797</OMIM>
          <Haploinsufficiency last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000138.5(FBN1):c.4878del (p.Phe1626fs)</Name>
      <CanonicalSPDI>NC_000015.10:48465631:AAA:AA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="48465632" stop="48465632" display_start="48465632" display_stop="48465632" variantLength="1" positionVCF="48465631" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="48757829" stop="48757829" display_start="48757829" display_stop="48757829" variantLength="1" positionVCF="48757828" referenceAlleleVCF="CA" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>F1626fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.48465634del" Assembly="GRCh38">
            <Expression>NC_000015.10:g.48465634del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.48757831del" Assembly="GRCh37">
            <Expression>NC_000015.9:g.48757831del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008805.2" sequenceAccession="NG_008805" sequenceVersion="2" change="g.185157del">
            <Expression>NG_008805.2:g.185157del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000138.5" sequenceAccession="NM_000138" sequenceVersion="5" change="c.4878del" MANESelect="true">
            <Expression>NM_000138.5:c.4878del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000129.3" sequenceAccession="NP_000129" sequenceVersion="3" change="p.Phe1626fs">
            <Expression>NP_000129.3:p.Phe1626fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_778" sequenceAccession="LRG_778">
            <Expression>LRG_778:g.185157del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_778t1" sequenceAccession="LRG_778t1" change="c.4878delT">
            <Expression>LRG_778t1:c.4878delT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2043314537" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000138.5(FBN1):c.4878del (p.Phe1626fs) AND Marfan syndrome" Accession="RCV001312197" Version="1">
        <ClassifiedConditionList TraitSetID="5402">
          <ClassifiedCondition DB="MedGen" ID="C0024796">Marfan syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-03-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-03-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-03-14" MostRecentSubmission="2021-03-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="5402" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2645" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MARFAN SYNDROME, TYPE I</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Marfan syndrome, classic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Marfan syndrome</ElementValue>
                <XRef ID="MONDO:0007947" DB="MONDO" />
                <XRef ID="19346006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Marfan syndrome type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Marfan's syndrome</ElementValue>
                <XRef ID="Marfan+syndrome/4466" DB="Genetic Alliance" />
                <XRef ID="19346006" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MFS</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MFS1</ElementValue>
                <XRef Type="MIM" ID="154700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6975" />
                <XRef ID="6975" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">FBN1-related Marfan syndrome (Marfan syndrome), a systemic disorder of connective tissue with a high degree of clinical variability, comprises a broad phenotypic continuum ranging from mild (features of Marfan syndrome in one or a few systems) to severe and rapidly progressive neonatal multiorgan disease. Cardinal manifestations involve the ocular, skeletal, and cardiovascular systems. Ocular findings include myopia (&gt;50% of affected individuals); ectopia lentis (seen in approximately 60% of affected individuals); and an increased risk for retinal detachment, glaucoma, and early cataracts. Skeletal system manifestations include bone overgrowth and joint laxity; disproportionately long extremities for the size of the trunk (dolichostenomelia); overgrowth of the ribs that can push the sternum in (pectus excavatum) or out (pectus carinatum); and scoliosis that ranges from mild to severe and progressive. The major morbidity and early mortality in Marfan syndrome relate to the cardiovascular system and include dilatation of the aorta at the level of the sinuses of Valsalva (predisposing to aortic tear and rupture), mitral valve prolapse with or without regurgitation, tricuspid valve prolapse, and enlargement of the proximal pulmonary artery. Severe and prolonged regurgitation of the mitral and/or aortic valve can predispose to left ventricular dysfunction and occasionally heart failure. With proper management, the life expectancy of someone with Marfan syndrome approximates that of the general population.</Attribute>
                <XRef ID="NBK1335" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">FBN1-Related Marfan Syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301510</ID>
                <ID Source="BookShelf">NBK1335</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987429</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, 2012">
                <ID Source="PubMed">22237449</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="CSANZ, 2007">
                <ID Source="PubMed">17188935</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AHA, 2004">
                <ID Source="PubMed">15184297</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2007">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Marfan.pdf</URL>
                <CitationText>Orphanet, Marfan Syndrome, 2007</CitationText>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Loeys et al., 2010">
                <ID Source="PubMed">20591885</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2013">
                <ID Source="PubMed">24081994</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="284963" DB="Orphanet" />
              <XRef ID="558" DB="Orphanet" />
              <XRef ID="C0024796" DB="MedGen" />
              <XRef ID="MONDO:0007947" DB="MONDO" />
              <XRef Type="MIM" ID="154700" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2959249" SubmissionDate="2021-03-03" DateLastUpdated="2021-03-14" DateCreated="2021-03-14">
        <ClinVarSubmissionID localKey="LRG_778t1:c.4878delT|OMIM:154700" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001502659" DateUpdated="2021-03-14" DateCreated="2021-03-14" Type="SCV" Version="1" SubmitterName="MNM Diagnostics" OrgID="507622" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-03-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>According to ACMG Guidelines, the variant meets the following criteria of pathogenicity: PVS1, PS2, PM1, PM2, PP3, PP4. This is a de novo variant of heterozygotic single nucleotide deletion (thymine in c.4878 position of FBN1 gene) resulting in phenylalanine to leucine substitution at p.1626, ORF shift and early stop codon leading to truncated protein. Mutations in FBN1 gene are responsible for Marfan Syndrom (MFS) observed as well in the proband.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>de novo</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <TypePlatform>whole genome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <Comment>Other, likely bening variant (NM_001851.5:c.1816C&gt;T resulting in a missense mutation in COL9A1 protein) was also observed in the patient.</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FBN1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">LRG_778t1:c.4878delT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="154700" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9192778</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2959249" TraitType="Disease" MappingType="XRef" MappingValue="154700" MappingRef="OMIM">
        <MedGen CUI="C0024796" Name="Marfan syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>